Read by QxMD icon Read

Biology of Blood and Marrow Transplantation

Aimaz Afrough, Rima M Saliba, Amir Hamdi, Medhavi Honhar, Ankur Varma, A Megan Cornelison, Gabriela Rondon, Simrit Parmar, Nina D Shah, Qaiser Bashir, Chitra Hosing, Uday Popat, Donna M Weber, Sheeba Thomas, Robert Z Orlowski, Richard E Champlin, Muzaffar H Qazilbash
BACKGROUND: With the availability of immunomodulatory agents (IMiD) and proteasome inhibitors (PI), most patients with immunoglobulin light chain amyloidosis (AL) receive induction therapy prior to autologous hematopoietic stem cell transplant (auto-HCT). In this study, we evaluated the type of induction therapy and its impact on the outcome of auto-HCT in AL. METHODS: We identified 128 patients with AL who underwent high-dose chemotherapy and auto- HCT at our institution between 1997 and 2013...
July 14, 2018: Biology of Blood and Marrow Transplantation
Vedran Radojcic, Catherine J Lee, Daniel R Couriel
Curative therapies can leave a lasting burden on cancer patients. Survivorship issues are becoming a "pandemic of treatment success" and include not only short- and long-term treatment sideeffects, development of subsequent cancers, and psychosocial issues, but also a lasting financial toll. It is increasingly recognized that cancer survivorship is tightly associated with a decline in financial health and the unavoidable impact of high associated medical care costs extending beyond those accrued during the initial treatment...
July 14, 2018: Biology of Blood and Marrow Transplantation
Chikara Ogimi, Hu Xie, Wendy M Leisenring, Jane M Kuypers, Keith R Jerome, Angela P Campbell, Janet A Englund, Michael Boeckh, Alpana Waghmare
INTRODUCTION: Recent data suggest human rhinovirus (HRV) is associated with lower respiratory tract infection and mortality in hematopoietic cell transplant (HCT) recipients. Examining risk factors for prolonged viral shedding may provide critical insight for the development of novel therapeutics and help inform infection prevention practices. Our objective was to identify risk factors for prolonged shedding of HRV post-HCT. MATERIALS AND METHODS: We prospectively collected weekly nasal samples from allogeneic HCT recipients from day 0 to day 100 post-transplant, and performed real-time RT-PCR (12/2005 to 2/2010)...
July 12, 2018: Biology of Blood and Marrow Transplantation
Thomas Heinicke, Myriam Labopin, Christoph Schmid, Emmanuelle Polge, Gérard Socié, Didier Blaise, Ghulam J Mufti, Anne Huynh, Arne Brecht, Marie-Pierre Ledoux, Jean Yves Cahn, Noel Milpied, Christof Scheid, Yosr Hicheri, Mohamad Mohty, Bipin N Savani, Arnon Nagler
BACKGROUND: Busulfan/fludarabine (BuFlu) is a widely used conditioning regimen for patients with myeloid malignancies. The sequential FLAMSA protocol (fludarabine+Ara-C+amsacrine chemotherapy followed by either cyclophosphamide and total body irradiation (FLAMSA-TBI) or cyclophosphamide and busulfan (FLAMSA-Bu)) has shown remarkable activity in high risk AML patients. Here, we compare the outcomes of AML patients transplanted in CR1 or CR2 after conditioning with BuFlu or FLAMSA. METHODS: Eligible patients had their first allogeneic stem cell transplantation (alloSCT) for AML in CR1 or CR2 between 1/2005 and 6/2016...
July 12, 2018: Biology of Blood and Marrow Transplantation
Arjun Datt Law, Maria Queralt Salas, Wilson Lam, Fotios V Michelis, Santhosh Thyagu, Dennis Dong Hwan Kim, Jeffrey Howard Lipton, Rajat Kumar, Hans Messner, Auro Viswabandya
BACKGROUND: Haploidentical hematopoietic stem cell transplantation (haploSCT) with conditioning regimens using post-transplant cyclophosphamide (PTCy) for peripheral blood stem cell (PBSC) grafts is limited by comparably higher rates of acute and chronic graft-versus-host disease (GVHD). Anti-thymocyte globulin (ATG) may mitigate this risk. We evaluated haploSCT after reduced intensity conditioning (RIC) with ATG, PTCy & cyclosporine to prevent rejection and GVHD. METHODS: Fifty adults underwent haploSCT from August 2016-February 2018...
July 12, 2018: Biology of Blood and Marrow Transplantation
Mahasweta Gooptu, Haesook T Kim, Yi-Bin Chen, Witold Rybka, Andrew Artz, Michael Boyer, Laura Johnston, Jim McGuirk, Thomas C Shea, Madan Jagasia, Paul J Shaughnessy, Carol G Reynolds, Marie Fields, Edwin P Alyea, Vincent T Ho, Frank Glavin, John F Dipersio, Peter Westervelt, Jerome Ritz, Robert J Soiffer
INTRODUCTION: We recently conducted a randomized double-blind study in which we demonstrated that moderate/severe cGVHD, but not cGVHD free survival, was reduced in patients receiving ATLG (Neovii) versus placebo. In a companion study, we performed immunophenotypic analysis, to determine the impact of ATLG on immune reconstitution (IR) and to correlate IR with clinical outcomes. METHODS: The randomized study (n=254) included patients (18-65 years) who underwent myeloablative transplants for AML/MDS/ALL from HLA-matched unrelated donors...
July 10, 2018: Biology of Blood and Marrow Transplantation
Ji-Young Lim, Da-Bin Ryu, Mi-Young Park, Sung-Eun Lee, Gyeongsin Park, Tai-Gyu Kim, Chang-Ki Min
Myeloid derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells with anti-inflammatory activity and expanded murine MDSCs are capable of attenuating preclinical acute GVHD (AGVHD) severity. Two murine CGVHD models were utilized to evaluate the effectiveness of ex-vivo cultured human cord blood-MDSCs (hCB-MDSCs) in chronic graft-versus-host disease (CGVHD). First, GVHD recipients surviving in a classical C57BL/6 into MHC-mismatched BALB/c AGVHD model developed CGVHD. Second, donor pretreatment with G-CSF induced CGVHD...
July 10, 2018: Biology of Blood and Marrow Transplantation
Hemn Mohammadpour, Wei Du, Rachel O'Neil, Saeed Khalili, Jingxin Qiu, Elizabeth A Repasky, Philip L McCarthy, Xuefang Cao
Graft-versus-host disease (GVHD) is a serious complication after allogeneic hematopoietic cell transplantation (allo-HCT) that limits the therapeutic potential of this treatment. Host antigen-presenting cells (APCs) play a vital role in activating donor T cells which subsequently use granzyme B (GzmB) and other cytotoxic molecules to damage host normal tissues. Serine protease inhibitor 6 (Spi6), known as the sole endogenous inhibitor of GzmB, has been implicated in protecting T cells and APCs against GzmB-inflicted damage...
July 10, 2018: Biology of Blood and Marrow Transplantation
Damiano Rondelli
No abstract text is available yet for this article.
July 9, 2018: Biology of Blood and Marrow Transplantation
Kyung Taek Hong, Hyoung Jin Kang, Jung Yoon Choi, Che Ry Hong, Jung-Eun Cheon, June Dong Park, Kyung Duk Park, Sang Hoon Song, Kyung-Sang Yu, In-Jin Jang, Hee Young Shin
Haploidentical hematopoietic stem cell transplantation (haplo-HSCT) with post-transplantation cyclophosphamide (PTCy) was performed previously in adults using a non-myeloablative conditioning regimen and bone marrow as a graft source. In an effort to reduce relapse rates, myeloablative conditioning regimens with higher intensities are now used. We used an intensive daily pharmacokinetic monitoring method for busulfan dosing in children for effective myeloablation and to reduce toxicity. Here, we report the retrospective results of 34 patients (median age, 11...
July 5, 2018: Biology of Blood and Marrow Transplantation
Jocelyn S Gandelman, D Joanne Song, Heidi Chen, Brian G Engelhardt, Yi-Bin Chen, William B Clark, Cynthia R Giver, Edmund K Waller, Dae Kwang Jung, Madan Jagasia
Extracorporeal Photopheresis (ECP) is an accepted treatment for chronic-graft-versus-host disease (cGVHD), however, the mechanism of action is unclear. We conducted a prospective multicenter clinical trial to assess ECP response rates using the 2005 NIH consensus criteria, as well as the relationship between regulatory T cells (Tregs) and treatment response (NCT01324908). 83 patients with any NIH subtype of cGVHD were enrolled, irrespective of number of prior lines of treatment, and 6 were subsequently excluded due to of absence of follow-up from cancer relapse, infection or study withdrawal...
July 5, 2018: Biology of Blood and Marrow Transplantation
Yueh Z Lee, Esther Akinnagbe-Zusterzeel, Kenneth A Fowler, James M Coghill
Acute graft-versus-host disease (aGVHD) remains a barrier to the success of allogeneic hematopoietic stem cell transplantation (HSCT). In mice, studies have demonstrated that donor conventional T cells traffic into host secondary lymphoid tissues early after transplant, and that this process is critical for the development of disease. As a result, the measurement of cellular proliferation within lymphoid sites early after transplant might be a useful approach for predicting aGVHD in humans. 18F-3'-deoxy-3' -fluorothymidine (FLT) Positron Emission Tomography (PET) imaging has recently emerged as a functional imaging modality in oncology patients...
July 4, 2018: Biology of Blood and Marrow Transplantation
Bettina M Knoll, Driele Peixoto, Sophia Koo, Sarah P Hammond, Vincent T Ho, Joseph H Antin, Robert J Soiffer, Corey Cutler, Francisco M Marty
No abstract text is available yet for this article.
June 30, 2018: Biology of Blood and Marrow Transplantation
Joshua A Hill, Steven A Pergam, Michael Boeckh, Filippo Milano
No abstract text is available yet for this article.
June 30, 2018: Biology of Blood and Marrow Transplantation
Nandita Khera, Lih-Wen Mau, Ellen M Denzen, Christa Meyer, Kate Houg, Stephanie J Lee, Mary M Horowitz, Linda J Burns
BACKGROUND: Barriers and facilitators to adoption of results of clinical trials are substantial and poorly understood. We sought to examine whether the results of the randomized, multicenter Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0201 study comparing peripheral blood (PB) with bone marrow (BM) stem cells for unrelated donor (URD) hematopoietic cell transplantation (HCT) changed practice from PB to BM graft utilization, and explored factors that impact graft selection and translation of research results into practice...
June 30, 2018: Biology of Blood and Marrow Transplantation
Francis Ayuk, Dietrich W Beelen, Martin Bornhäuser, Matthias Stelljes, Tatjana Zabelina, Jürgen Finke, Guido Kobbe, Daniel Wolff, Eva-Maria Wagner, Maximilian Christopeit, Christoph Schmid, Hellmut Ottinger, Christoph Groth, Christoph Faul, Hartmut Bertz, Elena Rachlis, Christine Wolschke, Johannes Schetelig, Peter A Horn, Joannis Mytilineos, Martina Guellstorf, Reinhard Kelsch, Katharina Fleischhauer, Nicolaus Kröger, Wolfgang Bethge
Increasing donor-recipient HLA-disparity is associated with negative outcome of allogeneic hematopoietic stem cell transplantation (HSCT), but its relative relevance amidst non-HLA donor characteristic is not well established. We addressed this question in 3215 HSCT performed between 2005 and 2013 in Germany for AML or MDS. Donors were HLA-matched related (MRD; n=872) or unrelated (10/10MUD, n=1553), or HLA-mismatched unrelated (<10/10MMUD, n= 790). Overall survival (OS) was similar after MRD compared to 10/10MUD HSCT, reflecting opposing hazards of relapse (hazards ratio [HR] 1...
June 29, 2018: Biology of Blood and Marrow Transplantation
M Hasib Sidiqi, Mohammed Aljama, Dragan Jevremovic, Eli Muchtar, Francis K Buadi, Rahma Warsame, Martha Q Lacy, Angela Dispenzieri, David Dingli, Wilson I Gonsalves, Shaji Kumar, Prashant Kapoor, Taxiarchis Kourelis, Nelson Leung, William J Hogan, Morie Gertz
Hematologic response has emerged as a powerful prognostic factor for survival in patients with immunoglobulin light chain amyloidosis. Patients achieving a complete response (CR), based on serum and urine analysis, survive longest. However data regarding the impact of bone marrow features post therapy on response and survival is limited. We evaluated impact of achieving a stringent complete response (sCR), defined as undetectable bone marrow clonal plasma cells by flow cytometry, in patients with AL amyloidosis receiving an autologous stem cell transplant...
June 29, 2018: Biology of Blood and Marrow Transplantation
Jesús Duque-Afonso, Gabriele Ihorst, Miguel Waterhouse, Robert Zeiser, Ralph Wäsch, Hartmut Bertz, Joachim Müller-Quernheim, Jürgen Finke, Reinhard Marks, Antje Prasse
Lung function deterioration contributes to treatment-related morbidity and mortality in patients after allogeneic hematopoietic cell transplantation (allo-HCT). Better understanding of impaired lung function including bronchiolitis obliterans syndrome (BOS) as chronic manifestation of Graft-versus-Host-Disease (GvHD) might improve outcomes of patients after allo-HCT. In order to detect early pulmonary function tests abnormalities associated with BOS incidence and outcome after allo-HCT, we performed a retrospective analysis of homogenous-treated 445 patients (median age 61...
June 28, 2018: Biology of Blood and Marrow Transplantation
Keith M Sullivan, Navneet S Majhail, Christopher Bredeson, Paul A Carpenter, Soumya Chatterjee, Leslie J Crofford, George E Georges, Richard A Nash, Marcelo C Pasquini, Stefanie Sarantopoulos, Jan Storek, Bipin Savani, E William St Clair
Systemic sclerosis is a progressive inflammatory disease that is frequently fatal and has limited treatment options. High-dose chemotherapy with autologous hematopoietic cell transplantation (AHCT) has been evaluated as treatment for this disease in observational studies, multicenter randomized controlled clinical trials, and meta-analyses. On behalf of the American Society for Blood and Marrow Transplantation (ASBMT), a panel of experts in transplantation and rheumatology was convened to review available evidence and make a recommendation on AHCT as an indication for systemic sclerosis...
June 25, 2018: Biology of Blood and Marrow Transplantation
Raphael Teipel, Uta Oelschlägel, Katrin Wetzko, Maria Schmiedgen, Michael Kramer, Elke Rücker-Braun, Kristina Hölig, Malte von Bonin, Katharina Heidrich, Anke Fuchs, Rainer Ordemann, Frank Kroschinsky, Martin Bornhäuser, Gero Hütter, Helmuth Schmidt, Gerhard Ehninger, Johannes Schetelig, Falk Heidenreich
This study was conducted to characterize and compare peripheral blood stem cell grafts from healthy donors, who underwent G-CSF-mobilization and subsequently received one dose of plerixafor, after insufficient stem cell yields were achieved at the first apheresis. Aliquots from 35 donors were collected from the first apheresis after mobilization with G-CSF alone, and from the second apheresis after additional plerixafor administration. Samples were freshly analyzed for cellular subsets by 8-color flow-cytometry...
June 20, 2018: Biology of Blood and Marrow Transplantation
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"